Guerbet

Equities

GBT

FR0000032526

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris Other stock markets 11:35:21 2024-04-26 am EDT			5-day change	1st Jan Change
37.4 ^EUR	+4.32%		+10.65%	+91.79%

03:40pm	Guerbet: quarterly sales up by nearly 8	CF
Apr. 25	Guerbet SA Provides Earnings Guidance for the Year 2024	CI

Guerbet Sa Announces Consolidated Revenue for the First Half Ended June 30, 2020

July 23, 2020 at 11:46 am EDT

Guerbet SA announced consolidated revenue for the first half ended June 30, 2020. For the period the company reported revenue at current exchange rate of EUR 363.7 million or at constant exchange rate of EUR 367.1 million against EUR 400.6 million a year ago.

Latest news about Guerbet

Guerbet: quarterly sales up by nearly 8	09:40am	CF
Guerbet SA Provides Earnings Guidance for the Year 2024	Apr. 25	CI
Guerbet: CE certificate for a platform	Apr. 09	CF
Intrasense: awarded CE certificate	Apr. 09	CF
Guerbet SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Guerbet: results exceed expectations, share price rises	Mar. 21	CF
Guerbet: two appointments to the executive committee	Mar. 11	CF
CAC40: gloomy end to the week, timid weekly gain (+0.7%)	Feb. 09	CF
Guerbet: sales growth of 4% by 2023	Feb. 09	CF
Guerbet: positive opinion from the CHMP for Elucirem	23-10-12	CF
Guerbet SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Guerbet: decline in half-year EBITDA margin	23-09-21	CF
Guerbet SA(ENXTPA:GBT) dropped from S&P Global BMI Index	23-09-18	CI
Guerbet: back to growth, share price rises	23-07-21	CF
Guerbet wins prostate cancer challenge	23-07-17	CF
Guerbet: two management appointments	23-07-10	CF
Guerbet: agreement on AI for medical imaging	23-06-19	CF
Intrasense: joins Guerbet Group following successful takeover bid	23-06-12	CF
Guerbet: Intrasense joins the group	23-06-12	CF
Guerbet: holds 56.5% of Intrasense following reopening of its offer	23-06-09	CF
Guerbet SA completed the acquisition of 17.82% stake in Intrasense SA.	23-06-04	CI
Global markets live: Boeing, Google, Meta, Sonos...	23-05-29
Guerbet: changes within the Board of Directors	23-05-26	CF
Guerbet Announces Management Appointments	23-05-26	CI
Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) Injection	23-05-23	CI

Chart Guerbet

Duration

Period

More charts

Company Profile

Guerbet is a European leader in producing and selling contrast products for medical imaging. The group's products make it possible to visualize different organs and the lymphatic and vascular systems of the human body by making them opaque. Net sales break down by product family as follows: - X-ray imaging products (55.4%); - MRI products (32.7%); - other (11.9%): contrast products for echography and nuclear medicine, fine chemicals products. At the end of 2023 the group had 8 production sites located in France (4), the United States (2), Ireland and Brazil. Europe accounts for 39.7% of net sales.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Guerbet

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.85 EUR

Average target price

38.63 EUR

Spread / Average Target

+7.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Imaging Systems

	1st Jan change	Capi.
GUERBET	+91.79%	483M
SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.	-5.77%	14.49B
IRAY TECHNOLOGY COMPANY LIMITED	-40.71%	2.78B
SONOSCAPE MEDICAL CORP.	-12.92%	2.42B
BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.	-8.78%	1.47B
CORETAG, INC.	-.--%	1.12B
NANO-X IMAGING LTD.	+40.35%	515M
VIEWORKS CO., LTD.	+1.67%	183M
INTROMEDIC CO., LTD.	-.--%	168M
DRTECH CORPORATION	-29.34%	164M

Medical Imaging Systems